David Kallend Selected Research

Inflammation (Inflammations)

1/2021	Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
7/2014	The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
10/2013	Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
4/2012	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
8/2011	Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
1/2011	Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Kallend Research Topics

Disease

12	Coronary Disease (Coronary Heart Disease) 01/2020 - 04/2004
10	Cardiovascular Diseases (Cardiovascular Disease) 12/2022 - 07/2009
9	Acute Coronary Syndrome 01/2020 - 12/2009
6	Inflammation (Inflammations) 01/2021 - 01/2011
3	Hypercholesterolemia 01/2023 - 05/2004
3	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2004
3	Atherosclerotic Plaque (Atheroma) 01/2018 - 08/2011
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018 - 04/2005
3	Myocardial Infarction 10/2017 - 11/2012
3	Atherosclerosis 01/2017 - 04/2004
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 11/2018
2	Hypertension (High Blood Pressure) 06/2015 - 07/2009
2	Unstable Angina 06/2015 - 11/2012
1	Liver Diseases (Liver Disease) 03/2022
1	Necrosis 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Prediabetic State (Prediabetes) 01/2020
1	Homozygous Familial Hypercholesterolemia 01/2020
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Heart Failure 10/2017
1	Left Ventricular Dysfunction 10/2017
1	Injection Site Reaction 01/2017
1	Arteritis 01/2017
1	Vascular Calcification 01/2016
1	Myocardial Ischemia (Ischemic Heart Diseases) 06/2015
1	Stroke (Strokes) 06/2015
1	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 12/2014
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 12/2014
1	Ischemic Stroke 11/2012
1	Heart Arrest (Cardiac Arrest) 11/2012

Drug/Important Bio-Agent (IBA)

14	dalcetrapibIBA 01/2020 - 07/2009
9	LDL CholesterolIBA 01/2023 - 05/2004
8	ALN-PCSIBA 01/2023 - 01/2017
7	Cholesterol Ester Transfer ProteinsIBA 01/2020 - 07/2009
7	LipidsIBA 12/2016 - 10/2004
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 06/2015
5	HDL CholesterolIBA 01/2020 - 02/2010
4	oxidized low density lipoproteinIBA 01/2023 - 01/2019
4	Small Interfering RNA (siRNA)IBA 01/2023 - 01/2019
4	HDL LipoproteinsIBA 01/2020 - 11/2012
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2012
3	Lipoproteins (Lipoprotein)IBA 12/2016 - 07/2014
3	Rosuvastatin Calcium (Crestor)FDA Link 10/2004 - 04/2004
2	Proprotein Convertase 9IBA 01/2023 - 01/2020
2	MDCO-216IBA 01/2018 - 12/2016
2	Atorvastatin (Lipitor)FDA Link 06/2015 - 04/2004
2	Triglycerides (Triacylglycerol)IBA 06/2015 - 05/2004
1	Antisense OligonucleotidesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	omega-Chloroacetophenone (Mace)IBA 01/2020
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020
1	SodiumIBA 01/2020
1	apolipoprotein A-I MilanoIBA 01/2018
1	Lipoprotein(a)IBA 01/2018
1	Mineralocorticoid Receptor AntagonistsIBA 10/2017
1	AldosteroneIBA 10/2017
1	Apolipoproteins AIBA 12/2016
1	CholesterolIBA 06/2015
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 12/2014
1	Phytosterols (Plant Sterols)IBA 12/2014
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 12/2014
1	ApolipoproteinsIBA 07/2014
1	Peroxidase (Myeloperoxidase)IBA 10/2013
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2012
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 04/2012
1	torcetrapibIBA 07/2009
1	Fenofibrate (CiL)FDA LinkGeneric 05/2004
1	Simvastatin (Zocor)FDA LinkGeneric 04/2004
1	Pravastatin (Pravachol)FDA LinkGeneric 04/2004

Therapy/Procedure

9	Therapeutics 12/2022 - 12/2009
2	Subcutaneous Injections 01/2020 - 01/2017
1	Intravenous Infusions 01/2018
1	Injections 01/2017
1	Resuscitation 11/2012
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 10/2004